90 related articles for article (PubMed ID: 28323755)
1. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Bolton Moore C; Capparelli EV; Samson P; Bwakura-Dangarembizi M; Jean-Philippe P; Worrell C; Heckman B; Purdue L; Spector SA; Benns A; Borkowsky W; Loftis A; Hawkins E; Wallis C; Chadwick EG;
AIDS; 2017 May; 31(8):1129-1136. PubMed ID: 28323755
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
[TBL] [Abstract][Full Text] [Related]
4. Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Chala A; Kitabi EN; Ahmed JH; Tadesse BT; Chaka TE; Makonnen E; Aklillu E
CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):783-794. PubMed ID: 36840416
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
Fletcher CV; Brundage RC; Fenton T; Alvero CG; Powell C; Mofenson LM; Spector SA
Clin Pharmacol Ther; 2008 Feb; 83(2):300-6. PubMed ID: 17609682
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.
Schackman BR; Haas DW; Park SS; Li XC; Freedberg KA
Pharmacogenomics; 2015 Dec; 16(18):2007-18. PubMed ID: 26607811
[TBL] [Abstract][Full Text] [Related]
7. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.
Bienczak A; Cook A; Wiesner L; Mulenga V; Kityo C; Kekitiinwa A; Walker AS; Owen A; Gibb DM; Burger D; McIlleron H; Denti P
J Antimicrob Chemother; 2017 Jan; 72(1):190-199. PubMed ID: 27707991
[TBL] [Abstract][Full Text] [Related]
8. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.
de Almeida TB; de Azevedo MCVM; Pinto JFDC; Ferry FRA; da Silva GAR; de Castro IJ; Baker P; Tanuri A; Haas DW; Cardoso CC
J Antimicrob Chemother; 2018 Sep; 73(9):2460-2467. PubMed ID: 29868865
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Impact of Efavirenz on Aflatoxin B1 Metabolism: Insights from a Physiologically Based Pharmacokinetic Model and a Human Liver Microsome Study.
Lootens O; De Boevre M; Gasthuys E; De Saeger S; Van Bocxlaer J; Vermeulen A
Toxins (Basel); 2024 Jun; 16(6):. PubMed ID: 38922153
[TBL] [Abstract][Full Text] [Related]
10. Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype.
Eniayewu O; Akinloye A; Shenkoya B; Azuka U; Bolaji O; Adejuyigbe E; Owen A; Olagunju A
Pharmacogenet Genomics; 2024 Jun; ():. PubMed ID: 38934229
[TBL] [Abstract][Full Text] [Related]
11. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.
Sivay MV; Li M; Piwowar-Manning E; Zhang Y; Hudelson SE; Marzinke MA; Amico RK; Redd A; Hendrix CW; Anderson PL; Bokoch K; Bekker LG; van Griensven F; Mannheimer S; Hughes JP; Grant R; Eshleman SH;
J Acquir Immune Defic Syndr; 2017 Jul; 75(3):271-279. PubMed ID: 28328548
[TBL] [Abstract][Full Text] [Related]
12. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK;
Clin Infect Dis; 2017 Apr; 64(8):1006-1016. PubMed ID: 28329393
[TBL] [Abstract][Full Text] [Related]
13. Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.
Herrick JA; Legrand F; Gounoue R; Nchinda G; Montavon C; Bopda J; Tchana SM; Ondigui BE; Nguluwe K; Fay MP; Makiya M; Metenou S; Nutman TB; Kamgno J; Klion AD
Clin Infect Dis; 2017 Apr; 64(8):1017-1025. PubMed ID: 28329346
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
[TBL] [Abstract][Full Text] [Related]
15. Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine for the Prevention of Malaria Among HIV-Infected Pregnant Women.
Natureeba P; Kakuru A; Muhindo M; Ochieng T; Ategeka J; Koss CA; Plenty A; Charlebois ED; Clark TD; Nzarubara B; Nakalembe M; Cohan D; Rizzuto G; Muehlenbachs A; Ruel T; Jagannathan P; Havlir DV; Kamya MR; Dorsey G
J Infect Dis; 2017 Jul; 216(1):29-35. PubMed ID: 28329368
[TBL] [Abstract][Full Text] [Related]
16. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
17. α7-Nicotinic acetylcholine receptor inhibition by indinavir: implications for cognitive dysfunction in treated HIV disease.
Ekins S; Mathews P; Saito EK; Diaz N; Naylor D; Chung J; McMurtray AM
AIDS; 2017 May; 31(8):1083-1089. PubMed ID: 28358738
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B serological markers and plasma DNA concentrations.
Price H; Dunn D; Zachary T; Vudriko T; Chirara M; Kityo C; Munderi P; Spyer M; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
AIDS; 2017 May; 31(8):1109-1117. PubMed ID: 28328795
[TBL] [Abstract][Full Text] [Related]
19. Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.
Slogrove AL; Clayden P; Abrams EJ
Curr Opin HIV AIDS; 2017 Jul; 12(4):359-368. PubMed ID: 28426519
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
